Zaika A.I., Slade N., Erster S., Sansome C., Joseph T.W., Pearl M., Chalas E., Moll U.M. DeltaNp73, a dominant negative inhibitor of wild type p53 and TA p73, is upregulated in human tumors. J Exp Med (2002) 196: 765-780.
Slade N., Zaika A.I., Erster S., Moll U.M. DeltaNp73 stabilizes TAp73 proteins but compromises their function due to inhibitory hetero-oligomer formation. Cell Death Differ (2004) 11: 357-360.
Concin N., Becker K., Slade N., Erster S., Mueller-Holzner E., Ulmer H., Daxenbichler G., Zeimet A., Zeillinger R., Marth C., Moll U.M. Transdominant deltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res (2004) 64: 2449–2460.
Moll U.M., Slade N. p63 and p73: Roles in Development and Tumor Formation. Mol Cancer Res (2004) 2: 371-386.
Grollman A.P., Shibutani S., Moriya M., Miller F., Wu L., Moll M., Suzuki N., Fernandes A., Rosenquist T., Medverec Z., Jakovina K., Brdar B., Slade N., Turesky R.J., Goodenough A.K., Rieger R., Vukelić M., Jelaković B. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA (2007) 104: 12129-12134.
Slade N., Moll U.M., Brdar B., Zorić A., Jelaković B. p53 mutations as fingerprints for aristolochic acid – an environmental carcinogen in endemic (Balkan) nephropathy. MutatRes/Fund Mol M (2009) 663: 1-6.
Hofstetter G., Berger A., Fiegl H., Slade N., Zorić A., Holzer B., Schuster E., Mobus V.J., Reimer D., Daxenbichler G., Marth C., Zeimet A.G., Concin N.,Zeillinger R. Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene (2010) 29:1997-2004.
Slade N., Horvat A. Targeting p73 - A Potential Approach in Cancer Treatment. Curr Pharm Des (2011) 17: 591-602.
Moriya M., Slade N., Brdar B., Medverec Z., Tomić K., Jelaković B., Wu L., Truong S., Fernandes A., Grollman AP. TP53 Mutational signature for aristolochic acid: An environmental carcinogen. Int J Cancer (2011) 129:1532-1536.
Jelaković B., Karanović S., Vuković-Lela I., Miller F., Edwards K., Nikolić J., Tomić K.,Slade N., Brdar B., Turesky R., Stipanćić Ž, Dittrich D., Grollman A.P., Dickman K.G. Aristolactam-DNA Adducts in the Renal Cortex: Biomarkers of Environmental Exposure to Aristolochic Acid. Kidney Int (2012) 81:559-567.
Zorić A, Horvat A,Slade N. Differential effects of diverse p53 isoforms on TAp73 transcriptional activity and apoptosis. Carcinogenesis (2013) 34:522-529.
Laganović M, Bendix L, Rubelj I, Kirhmajer Vrkić M,Slade N, Vuković Lela I, Premužić V, Nilsson PM, Jelaković B. Reduced telomere length is not associated with early signs of vascular aging in young men born after intrauterine growth restriction: a paradox? J Hypertens (2014) 32:1613-1619.
Slade N., Zorić A., Horvat B., Vukšić M., Kostović I., Poljak Lj. Suppression of Smad-1 mRNA expression level by Smad-2 likely control dichotomy of NF-κB and Smads mediated activation. Immunobiology (2015) 220: 48-53.
Hanžić N, Horvat A, Bibić J, Unfried K, Jurkin T, Dražić G, Marijanović I, Slade N*, Gotić M*. Syntheses of gold nanoparticles and their impact on the cell cycle in breast cancer cells subjected to megavoltage X-ray irradiation. Mater Sci Eng C-Mater (2018) 91:486-495. *corresponding authors
Jazvinšćak Jembrek M., Slade N., Hof P.R., Šimić G. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease. Prog Neurobiol (2018) 168:104-127.
Knezović M., Ozretić P., Bujak M., Pezzè P., Ciribilli Y., Kaštelan Ž., Slade N.*, Hudolin T. The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis. Urol Oncol – Semin Ori (2019) 37(9):578.e1-578.e10. *corresponding author
Ozretić P., Hanžić N., Proust B., Sabol M., Trnski D., Radić M., Musani V., Ciribilli Y., Milas I., Puljiz Z., Herak Bosnar M., Levanat S., Slade N. Expression profiles of p53/p73, NME and GLI families in metastatic melanoma tissue and cell lines. Sci Rep (2019) 9(1):12470.
Radić M., Šoštar M., Weber I., Ćetković H., Slade N., Herak Bosnar M. The Subcellular Localization and Oligomerization Preferences of NME1/NME2 upon Radiation-Induced DNA Damage. Int J Mol Sci (2020) 21(7):2363.
Horvat, A.; Tadijan, A.; Vlašić, I.; Slade, N. p53/p73 Protein Network in Colorectal Cancer and Other Human Malignancies. Cancers (2021) 13, 2885.
Karanović S, Ardin M, Tang Z, Tomić K, Villar S, Renard C, Venturini E, Lorch AH, Lee DS, Stipančić Ž, Slade N, Brinar IV, Dittrich D, Karlović K, Borovečki F, Dickman KG, Olivier M, Grollman AP, Jelaković B, Zavadil J. Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure. Int J Cancer (2022) 150:374–386.
Tadijan A, Precazzini F, Hanžić N, Radić M, Gavioli N, Vlašić I, Ozretić P, Pinto L, Škreblin L, Barban G, Slade N*, Ciribilli Y*. Altered Expression of Shorter p53 Family Isoforms Can Impact Melanoma Aggressiveness. Cancers (2021) 13, 5231. * corresponding authors
Radić M, Vlašić I, Jazvinšćak Jembrek M, Horvat A, Tadijan A, Sabol M, Dužević M, Herak Bosnar M*, Slade N*. Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance. Int J Mol Sci (2022) 23, 9910. * corresponding authors